Sonoma Pharmaceuticals Inc (SNOA) FinancialsSNOASonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc (SNOA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Human Care, accounting for 92.6% of total sales, equivalent to $5.15M. Another important revenue stream is Animal Care. Understanding this composition is critical for investors evaluating how SNOA navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Sonoma Pharmaceuticals Inc maintains a gross margin of 40.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.62%, while the net margin is -5.15%. These profitability ratios, combined with a Return on Equity (ROE) of -42.52%, provide a clear picture of how effectively SNOA converts its operational activities into shareholder value.

In the context of the broader market, SNOA competes directly with industry leaders such as GELS and XRTX. With a market capitalization of $6.27M, it holds a significant position in the sector. When comparing efficiency, SNOA's gross margin of 40.23% stands against GELS's N/A and XRTX's N/A. Such benchmarking helps identify whether Sonoma Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Sonoma reported a total revenue of $5.56 million in Q4 2026, a 48.3% increase year-over-year, but still posted a net loss of $581,000. The gross margin has improved to 39.22%, indicating better cost management.